Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

Among rural people with chronic HCV infection and a history of injection drug use, a mobile telemedicine-based intervention vs enhanced usual care improves treatment initiation and cure rates.

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside ...

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

Poster of distinction at the Liver Meeting covered resistance analyses showing Phase II SVR12 efficacy was not impacted by NS5A resistant variants at baseline. Management noted that most HCV viral ...